Biovie Inc. · NASDAQ:BIVI
Biovie — B. Riley Neuroscience Conference 2021
19 slides from Biovie's conference presentation, Apr 29, 2021
Slide 1: Introduction to BioVie & NeurMedix
biovie Introduction to BioVie & NeurMedix B Riley Neuroscience Conference — April 2
Slide 2: Forward-looking Statements
| Forward-looking Statements ‘This document contains forward-looking statements made pursuant to the safe harbor provisions of the Private Secures Litigation Reform Act of 1995 that involve risks, uncertainties and assumptions that could cause BioVie's, ‘actual results and experience to differ mater
Slide 3: BioVie Background
BioVie Background + Clinical-stage biopharma company developing continuous infusion of terlipressin for the treatment of end-stage liver diseases + Announced the acquisition of the assets of NuerMedix yesterday + Appointed Cuong Do as President and Chief Executive Officer ©2023 Bee Pam ee
Slide 4: Compelling Asset Portfolio
Compelling Asset Portfolio BIV201 + Phase 2b trial in refractory ascites underway. Agreement with FDA on pivotal Phase 3 design * Continuous infusion terlipressin offers potential for safe therapy at home NE3107 + Pivotal Phase 3 stage asset + First-in-class small molecule inhibitor of inflammation
Slide 5: Opportunity with BIV201
| Opportunity with BIV201 $670M ‘Addressable US ‘ascites market size"; Projected BIV201 US. peak sales of $450 M with 67% penetration Sourcesnstes: 20,000 US patients targeted for B1V201 therapy 0 Number of FDA- approved drugs to specifically treat ascites Direct competitors Phase 2 Pivotal Phase 3
Slide 6: About NeurMedix Assets
| About NeurMedix Assets Years of research on inhibiting the pathological inflammatory cascade and insulin resistance in the brain Attractive assets/IP with remarkably broad applicability across diseases Rare Phase 3 asset with multiple follow-ons in other indications
Slide 7: Significance of Inflammation
Significance of Inflammation + Alzheimer's Disease + Multiple Myeloma + Parkinson's + Castrate-resistant Prostate Inulin esietence + Other inflammation-driven cancers + Other inflammation-driven such as diseases such as + Breast + Rheumatoid arthritis + Colon + Osteoporosis. * Gastric + Cystic fibro
Slide 8: Disrupting Biological Pathways
Disrupting Biological Pathways + Protein complexes are 3-D structures + Each complex could have multiple roles in multiple biological pathways + Challenge is to selectively change the conformation to: + Interrupt interactions in the deleterious pathway + While not disturbing beneficial interactions
Slide 9: NE3107: A Differentiated Molecule
NE3107: A Differentiated Molecule biovie + First-in-class molecule with desirable characteristics + Small molecule + Crosses blood-brain barrier + Excellent safety profile demonstrated in pre-clinical and clinical trials + Blocks neuroinflammation and insulin-resistance at the right time/place in pa
Slide 10: Extracellular Signal-Related Kinase (ERK)
Extracellular Signal-Related Kinase (ERK) Homeostatic Inflammatory Pathways Pathways via Ras/Raf/Mek via NFkB Critical player for both homeostasis and inflammation (and inflammation-induced insulin resistance)
Slide 11: NE3107 is Highly Selective
NE3107 is Highly Selective + Blocks only inflammatory phosphorylation of ERK Lam by MEK i + Breaks TNFa reactivation ore a + Inhibits inflammation- u induced insulin resistance + Does not appear to affect ERK phosphorylation by ERK ERKP Ras/Raf/MEK t + No effects on homeostasis
Slide 12: NE3107 Applicability
| NE3107 Applicability Alzheimer's + Reduces inflammation and insulin resistance implicated in Alzheimer's Disease Parkinson's Reduces inflammation, insulin resistance and parkinsonism in low dopamine environments Disease "INF reduction reduces levadopa induced dyskinesia IMM calls secrete cytokines
Slide 13: NE3107 vs. Others
| NE3107 vs. Others + Spe etene tot to suece-ne ne aces
Slide 14: Pipeline
l Pipeline Paes | ct | rent [res | res Alzheimer’s Ascites > Parkinson's* Multiple Myeloma Prostate Cancer * Drug-drug interaction study with levodopa required to proceed to Phase 2
Slide 15: Catalysts & Timelines (US)
l Catalysts & Timelines (US)
Slide 16: Next Steps
Next Steps + Advance clinical programs + Expand leadership to pursue opportunities + Finalize development plans
Slide 17: Recap
Recap * BIV201 provides foundation + NeurMedix assets allow BioVie to address some of the greatest unmet needs in medicine + Delivers advances for patients + Generates returns for shareholders + Diversifies BioVie’s portfolio with unique assets transforming BioVie into a broad-based biopharma compan
Slide 18: R&D Day
l R&D Day + Wednesday, May 19" at 12:00 — 2:00 p.m. EDT * Opportunity to delve deeper into our R&D programs and plans
Slide 19: Thank You